利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

129 条记录 (耗时 0.029 秒)

    POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP
    6.
    发明申请
    POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP 审中-公开
    用于检测N-末端PRO-BNP的多环 - 单克隆ELISA测定

    公开(公告)号：US20090325195A1

    公开(公告)日：2009-12-31

    申请号：US12421409

    申请日：2009-04-09

    申请人： Michelle Davey ,  George Jackowski ,  Peter Kupchak ,  Eric Stanton

    发明人： Michelle Davey ,  George Jackowski ,  Peter Kupchak ,  Eric Stanton

    IPC分类号： G01N33/53

    CPC分类号： G01N33/74 ,  C07K16/26 ,  C07K2317/31 ,  C07K2317/34 ,  C12N5/163 ,  G01N33/535 ,  G01N33/543 ,  G01N33/545 ,  G01N33/6893 ,  G01N2333/58 ,  G01N2800/325 ,  G01N2800/56 ,  G01N2800/7019 ,  Y10S436/811 ,  Y10S530/80

    摘要： A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.

    摘要翻译： 公开了一种特异性和灵敏的体外ELISA测定和诊断测试试剂盒，用于测定各种体液中NT-proBNP蛋白的水平，其非限制性实例是血液，血清，血浆，尿液等。 NT-proBNP ELISA测定采用夹心ELISA技术测定人血浆中的NT-proBNP循环。 为获得具有针对人proBNP靶向氨基酸序列的特异性结合特性的抗体，重组人proBNP（或rhproBNP）被表达和纯化，用作免疫原。 随后通过连续亲和纯化从山羊血清中纯化特异性氨基酸序列的多克隆抗体（PAb）。 针对特定多肽产生单克隆抗体。 表达和纯化重组人NT-proBNP（或rhNT-proBNP），以获得用于校准人NT-proBNP的定量方法的材料。

    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
    8.
    发明授权
    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance 失效
    Interalpha胰蛋白酶抑制剂生物聚合物标志物表明胰岛素抵抗

    公开(公告)号：US07329501B2

    公开(公告)日：2008-02-12

    申请号：US11439587

    申请日：2006-05-23

    申请人： George Jackowski ,  John Marshall

    发明人： George Jackowski ,  John Marshall

    IPC分类号： G01N33/53

    CPC分类号： C07K14/8114 ,  Y10T436/24

    摘要： The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    摘要翻译： 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合，以使特定样品中可验证的生物聚合物的多样性最大化。 然后，在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力，以相对于识别所述生物聚合物的存在和/或不存在，预测疾病风险评估以及开发针对所述疾病的治疗途径。

    Protein biopolymer markers predictive of type II diabetes
    9.
    发明申请
    Protein biopolymer markers predictive of type II diabetes 审中-公开
    预测II型糖尿病的蛋白质生物聚合物标记物

    公开(公告)号：US20070031979A1

    公开(公告)日：2007-02-08

    申请号：US11580470

    申请日：2006-10-12

    申请人： George Jackowski ,  John Marshall

    发明人： George Jackowski ,  John Marshall

    IPC分类号： G01N33/50 ,  G01N33/543

    CPC分类号： C07K14/47 ,  Y10T436/24 ,  Y10T436/255

    摘要： The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    摘要翻译： 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合，以使特定样品中可验证的生物聚合物的多样性最大化。 然后，在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力，以相对于识别所述生物聚合物的存在和/或不存在，预测疾病风险评估以及开发针对所述疾病的治疗途径。

    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
    10.
    发明申请
    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance 审中-公开

    公开(公告)号：US20060211146A1

    公开(公告)日：2006-09-21

    申请号：US11439588

    申请日：2006-05-23

    申请人： George Jackowski ,  John Marshall

    发明人： George Jackowski ,  John Marshall

    IPC分类号： G01N33/543

    CPC分类号： C07K14/8114 ,  Y10T436/24

    摘要： The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.